The estimated Net Worth of David Palling is at least $834 Tausend dollars as of 26 June 2009. David Palling owns over 9,998 units of Amicus Therapeutics Inc stock worth over $383,631 and over the last 17 years David sold FOLD stock worth over $450,815.
David has made over 16 trades of the Amicus Therapeutics Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently David sold 9,998 units of FOLD stock worth $101,280 on 26 June 2009.
The largest trade David's ever made was exercising 20,000 units of Amicus Therapeutics Inc stock on 24 April 2008 worth over $12,800. On average, David trades about 3,804 units every 30 days since 2008. As of 26 June 2009 David still owns at least 34,040 units of Amicus Therapeutics Inc stock.
You can see the complete history of David Palling stock trades at the bottom of the page.
David's mailing address filed with the SEC is C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY, NJ, 08512.
Over the last 17 years, insiders at Amicus Therapeutics Inc have traded over $306,740,337 worth of Amicus Therapeutics Inc stock and bought 23,821,602 units worth $176,323,212 . The most active insiders traders include Advisors Llcperceptive Life..., Peter J Barris und Plc Gsk. On average, Amicus Therapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $830,419. The most recent stock trade was executed by Bradley L Campbell on 3 September 2024, trading 7,500 units of FOLD stock currently worth $64,575.
amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
Amicus Therapeutics Inc executives and other stock owners filed with the SEC include: